Business · 16/08/1994Updated: 10/16/2026 · 1 min read
Prospective Grant of Exclusive License: Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease and Cognitive Disorders
Summary
The National Institutes of Health (NIH) is contemplating the grant of an exclusive worldwide license to practice inventions related to acetylcholinesterase inhibitors for the treatment of Alzheimer's disease and cognitive disorders to CURE, Inc. of Baltimore, Maryland.